Since its founding 200 years ago as a traditional drug seller and after the establishment of Amato Pharmaceutical Products along with the formulation of BORRAGINOL® about 100 years ago, Amato has thought about the life and health of patients first and foremost and has been concerned with both product quality and the information quality.

Why does Amato emphasize engineering?

Historically, when Amato took up the challenges of creating new medicines and containers that increased product quality, there were almost no machines available on the market to produce these new items. In some cases, Amato worked in collaboration with machinery manufacturers to make improvements in existing machinery. That is why Amato emphasizes developing engineering internally to provide a driving force for its development.

Why was Amato the first to use the world’s first fully automated production line for forming and packaging of suppositories?

This was because Amato had already started to develop these systems internally and fully understood the concepts. Up to that time, there were various types of machines for making suppositories. However, Amato had already experimented over and over on machinery that would fully automate the process from the beginning to final packaging without the intervention of human hands. Ultimately in 1971, Amato introduced new equipment made in the then-West Germany. As a result of Amato’s experimentation with the prototypes with understanding of the concepts, it made it possible to quickly actualize the first production line with the world’s first fully automated machine and the second one. This then went into actual operation, because of Amato’s engineering creativity.

Why did Amato decide to build its new Sanda Plant?

Amato has had experience in manufacturing in six plants since its founding. These have been the Teramachi Plant, Konyamachi Plant, Nakanomachi Plant, and Saso Plant and Minami Satellite Plant as well as the Fukuchiyama Plant. These manufacturing centers have been well received by members of the local communities. The investment in the Sanda Plant was undertaken because of the need for a plant design that enables to incorporate with the increasingly sophisticated global Good Manufacturing Practices (GMPs), which are the criteria for manufacturing and quality control of pharmaceuticals and OTC preparations.